Government-Owned Inventions; Availability for Licensing, 38088-38089 [E7-13542]

Download as PDF 38088 Federal Register / Vol. 72, No. 133 / Thursday, July 12, 2007 / Notices rwilkins on PROD1PC63 with NOTICES inhibitors that are indicated for the treatment of cocaine abuse and ADHD. They bind with high affinity to the dopamine transporter and block dopamine uptake, but generally do not produce behavioral effects comparable to those produced by cocaine. In animal models of drug abuse, many benztropine analogs have been shown to (1) Reduce cocaine-induced locomotor stimulation, (2) have long-lasting effects, and (3) lack a significant abuse liability. This suggests they may be useful medications for the treatment of human diseases where dopamine-related behavior is compromised, especially in situations in which an (partial) agonist treatment is indicated. However, some of the reported analogs have limited or poor solubility in aqueous systems or poor stability characteristics. To remedy this, the 3position benzhydrylether moiety of the benztropine analogs was replaced with the isosteric benzhydrylamine system in order to reduce hydrolysis of the less stable ether function, observed in the benztropine series, and further reduce lipophilicity to ultimately increase water solubility and bioavailability for improved therapeutic formulation and utility. Inventors: Amy H. Newman et al. (NIDA). Publication: P Grundt; TA Kopajtic, JL Katz, AH Newman. N–8–substitutedbenztropinamine analogs as selective dopamine transporter ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5419–5423. Patent Status: U.S. Provisional Application No. 60/689,746 filed 10 Jun 2005 (HHS Reference No. E–089–2005/ 0–US–01); International Application No. PCT/US2006/22401 filed 07 Jun 2006, which published as WO 2006/135715 on 21 Dec 2006 (HHS Reference No. E– 089–2005/0–PCT–02). Licensing Status: Available for exclusive or non-exclusive licensing. Licensing Contact: Tara L. Kirby, Ph.D.; 301/435–4426; tarak@mail.nih.gov Dated: July 5, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–13541 Filed 7–11–07; 8:45 am] BILLING CODE 4140–01–P VerDate Aug<31>2005 16:42 Jul 11, 2007 Jkt 211001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Cyclic Phosphopeptide Inhibitors of Protein Phosphatase 2C Delta, Wip1 Description of Technology: This technology involves the development of specific peptides that can be used as anti-cancer agents, particularly as promoters of apoptosis. The inventors have modified the natural substrate of the Wip1 protein phosphatase in order to produce the inhibitors, allowing for specific and efficient inhibition of Wip1. These peptides represent the first Wip1 peptide inhibitors. The inhibitors can be combined with other proapoptosis therapeutics to improve patient survival, providing an advantage to previous pro-apoptosis approaches. Wip1 (PP2Cdelta or PPM1D) is a protein phosphatase that negatively regulates cell-cycle arrest and apoptosis by preventing p53-mediated cell-cycle arrest and apoptosis. Wip1 is overexpressed in several human cancers, including breast cancer, ovarian clear cell adenocarcinoma and neuroblastoma, suggesting it may play an important role in oncogenesis. Inhibiting Wip1 may be a necessary step for inducing apoptosis and prohibiting tumor growth, accentuating the need for Wip1-directed therapies. Because these peptide inhibitors are the first specific Wip1 inhibitors, they represent the first PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 opportunity to pursue this therapeutic strategy. Applications: Applicable as anticancer therapeutics for a wide variety of tumors, including breast cancer, ovarian cancer, and neuroblastomas. Inhibitors can also be combined with other cancer therapeutics. Advantages: Inhibitors are designed based on strucural similarity to the native substrate, providing a high degree of specificity to the target. First inhibitors directed to Wip1 as a target for cancer therapy. Benefits: Cancer is the second leading cause of death in the United States, with approximately 600,000 cancer-related deaths occurring in 2006 alone. Wip1 inhibitors may provide a social benefit by reducing that number or improving the quality/length of patient life. Furthermore, the cancer therapeutic market is expected to reach $27 billion by 2009. Because these molecules are the first inhibitors of Wip1, there is an opportunity to occupy a significant niche in that predicted market. Inventors: Ettore Appella et al. (NCI). U.S. Patent Status: U.S. Provisional Application No. 60/850,218 (HHS Reference No. E–288–2006/0–US–01). Licensing Contact: David A. Lambertson, Ph.D.; Phone: (301) 435– 4632; E-mail: lambertsond@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute Center for Cancer Research, Laboratory for Cell Biology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Cyclic Phosphopeptide Inhibitors of Protein Phosphatase 2C Delta, Wip1. Please contact John D. Hewes, Ph.D. at 301/435–3121 or hewesj@mail.nih.gov for more information. A Gene Therapy to Treat Lung Cancer Description of Technology: This invention relates to the identification of a new tumor suppressor gene named Caliban from Drosophila melanogaster and Serologically determined colon cancer antigen gene 1 (Sdccag1) from humans. Sdccag1 is inactive in human lung cancer cells but active in normal lung cells. When full length Caliban or Sdccag1 is expressed in human lung cancer cells they lose their tumorigenicity. This suggests that Caliban/Sdccag1 could be used as both a therapeutic and diagnostic for cancer. Applications: Using gene therapy to replace the inactive gene with full length Caliban/Sdccag1 to treat cancer(s); A diagnostic assay that can determine whether the tumor E:\FR\FM\12JYN1.SGM 12JYN1 Federal Register / Vol. 72, No. 133 / Thursday, July 12, 2007 / Notices suppressor Caliban/Sdccag1 gene product is functioning in cells. Advantages: Caliban/Sdccag1 can be easily adopted into already standard gene therapy applications; Provides a novel therapeutic and diagnostic target for cancer. Benefits: It is estimated that there will be approximately 160,000 deaths caused by lung cancer in 2007. This technology will help in improving the quality of life of lung cancer patients as well as other cancers. Additionally, the gene therapy market is now a multi-million dollar industry. Inventors: Mark A. Mortin (NICHD), Xiaolin Bi (NCI). U.S. Patent Status: Pending PCT Application PCT/US2006/022180, published as WO 2006/13316 (E–118– 2005/0–PCT–02). Licensing Contact: David A. Lambertson, Ph.D.; Phone: (301) 435– 4632; Fax: (301) 402–0220; E-mail: lambertsond@mail.nih.gov. Collaborative Research Opportunity: The National Institute of Child Health and Human Development is seeking statements of capability or interest from parties interested in collaborative research to obtain pre-clinical data to be used to further develop, evaluate, or commercialize Caliban/Sdccag1 as a novel therapeutic and diagnostic target for cancer and other diseases. Please contact John D. Hewes, Ph.D. at 301– 435–3121 or hewesj@mail.nih.gov for more information. Dated: July 5, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–13542 Filed 7–11–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health rwilkins on PROD1PC63 with NOTICES National Human Genome Research Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning VerDate Aug<31>2005 16:42 Jul 11, 2007 Jkt 211001 individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Human Genome Research Institute Special Emphasis Panel, GWA Phenotype and Exposure Measures. Date: July 19, 2007. Time: 12 p.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5635 Fishers Lane, Suite 4076, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Ken D. Nakamura, PhD, Scientific Review Administrator, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 5635 Fishers Lane, Suite 4076, MSC 9306, Rockville, MD 20852, 301–402–0838, nakamurk@mail.nih.gov. This note is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: July 6, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–3397 Filed 7–11–07; 8:45 am] 38089 information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Type 1 Diabetes— Rapid Access to Intervention Development Special Emphasis Panel, National Institute of Diabetes and Digestive and Kidney Diseases. Date: July 31, 2007. Time: 12 p.m. to 2 p.m. Agenda: To evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes and its complications. Place: 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Dr. Lisa Spain, Program Director, Immunobiology of Type 1 Diabetes and Autoimmune Endocrine Diseases, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda, MD 20892– 5460, 301–451–9871. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 98.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) BILLING CODE 4140–01–M Dated: July 3, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–3401 Filed 7–11–07; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–01–M National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Diabetes and Digestive and Kidney Disorders; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes. The outcome of the evaluation will be a decision whether NIDDK should support the request and make available contract resources for development of the potential therapeutic to improve the treatment or prevent the development of type 1 diabetes and its complications. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 National Institutes of Health National Institute of Environmental Health Sciences; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, Scientific Research Analysis in Bioinformatics and Allied Areas. E:\FR\FM\12JYN1.SGM 12JYN1

Agencies

[Federal Register Volume 72, Number 133 (Thursday, July 12, 2007)]
[Notices]
[Pages 38088-38089]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-13542]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Cyclic Phosphopeptide Inhibitors of Protein Phosphatase 2C Delta, Wip1

    Description of Technology: This technology involves the development 
of specific peptides that can be used as anti-cancer agents, 
particularly as promoters of apoptosis. The inventors have modified the 
natural substrate of the Wip1 protein phosphatase in order to produce 
the inhibitors, allowing for specific and efficient inhibition of Wip1. 
These peptides represent the first Wip1 peptide inhibitors. The 
inhibitors can be combined with other pro-apoptosis therapeutics to 
improve patient survival, providing an advantage to previous pro-
apoptosis approaches.
    Wip1 (PP2Cdelta or PPM1D) is a protein phosphatase that negatively 
regulates cell-cycle arrest and apoptosis by preventing p53-mediated 
cell-cycle arrest and apoptosis. Wip1 is overexpressed in several human 
cancers, including breast cancer, ovarian clear cell adenocarcinoma and 
neuroblastoma, suggesting it may play an important role in oncogenesis. 
Inhibiting Wip1 may be a necessary step for inducing apoptosis and 
prohibiting tumor growth, accentuating the need for Wip1-directed 
therapies. Because these peptide inhibitors are the first specific Wip1 
inhibitors, they represent the first opportunity to pursue this 
therapeutic strategy.
    Applications: Applicable as anti-cancer therapeutics for a wide 
variety of tumors, including breast cancer, ovarian cancer, and 
neuroblastomas. Inhibitors can also be combined with other cancer 
therapeutics.
    Advantages: Inhibitors are designed based on strucural similarity 
to the native substrate, providing a high degree of specificity to the 
target. First inhibitors directed to Wip1 as a target for cancer 
therapy.
    Benefits: Cancer is the second leading cause of death in the United 
States, with approximately 600,000 cancer-related deaths occurring in 
2006 alone. Wip1 inhibitors may provide a social benefit by reducing 
that number or improving the quality/length of patient life. 
Furthermore, the cancer therapeutic market is expected to reach $27 
billion by 2009. Because these molecules are the first inhibitors of 
Wip1, there is an opportunity to occupy a significant niche in that 
predicted market.
    Inventors: Ettore Appella et al. (NCI).
    U.S. Patent Status: U.S. Provisional Application No. 60/850,218 
(HHS Reference No. E-288-2006/0-US-01).
    Licensing Contact: David A. Lambertson, Ph.D.; Phone: (301) 435-
4632; E-mail: lambertsond@mail.nih.gov.
    Collaborative Research Opportunity: The National Cancer Institute 
Center for Cancer Research, Laboratory for Cell Biology, is seeking 
statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
Cyclic Phosphopeptide Inhibitors of Protein Phosphatase 2C Delta, Wip1. 
Please contact John D. Hewes, Ph.D. at 301/435-3121 or 
hewesj@mail.nih.gov for more information.

A Gene Therapy to Treat Lung Cancer

    Description of Technology: This invention relates to the 
identification of a new tumor suppressor gene named Caliban from 
Drosophila melanogaster and Serologically determined colon cancer 
antigen gene 1 (Sdccag1) from humans. Sdccag1 is inactive in human lung 
cancer cells but active in normal lung cells. When full length Caliban 
or Sdccag1 is expressed in human lung cancer cells they lose their 
tumorigenicity. This suggests that Caliban/Sdccag1 could be used as 
both a therapeutic and diagnostic for cancer.
    Applications: Using gene therapy to replace the inactive gene with 
full length Caliban/Sdccag1 to treat cancer(s); A diagnostic assay that 
can determine whether the tumor

[[Page 38089]]

suppressor Caliban/Sdccag1 gene product is functioning in cells.
    Advantages: Caliban/Sdccag1 can be easily adopted into already 
standard gene therapy applications; Provides a novel therapeutic and 
diagnostic target for cancer.
    Benefits: It is estimated that there will be approximately 160,000 
deaths caused by lung cancer in 2007. This technology will help in 
improving the quality of life of lung cancer patients as well as other 
cancers. Additionally, the gene therapy market is now a multi-million 
dollar industry.
    Inventors: Mark A. Mortin (NICHD), Xiaolin Bi (NCI).
    U.S. Patent Status: Pending PCT Application PCT/US2006/022180, 
published as WO 2006/13316 (E-118-2005/0-PCT-02).
    Licensing Contact: David A. Lambertson, Ph.D.; Phone: (301) 435-
4632; Fax: (301) 402-0220; E-mail: lambertsond@mail.nih.gov.
    Collaborative Research Opportunity: The National Institute of Child 
Health and Human Development is seeking statements of capability or 
interest from parties interested in collaborative research to obtain 
pre-clinical data to be used to further develop, evaluate, or 
commercialize Caliban/Sdccag1 as a novel therapeutic and diagnostic 
target for cancer and other diseases. Please contact John D. Hewes, 
Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.

    Dated: July 5, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E7-13542 Filed 7-11-07; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.